This hypothesis can only be supported if adrenochrome is made in the body, if it is an hallucinogen and if any substance which will neutralize its effect or inhibit its formation is therapeutic for schizophrenia. If these are not true the hypothesis is wrong. We therefore had to create research groups to test each of these sub postulates, a biochemical team to examine the chemistry of these reactions, a psychiatric team to study its hallucinogenic properties and a clinical team to test possible substances that would inhibit this reaction and be therapeutic. In our book The Hallucinogens we describe in detail our research. Is adrenochrome made in the body? After I discovered how to make pure crystalline adrenochrome our biochemical team led by Dr R Heacock studied its properties and the many reactions in which it participated. Dr Heacock became the world's expert on adrenochrome and its derivatives. Humphry was very pleased with the pure adrenochrome, beautiful crystals which were purplish red which formed a bright red solution which turned yellow when oxidized by the oxygen in the air. I gave him a small amount of the crystals. It was so stable it could be stored at room temperature. Humphry had a subtle sense of humor and enjoyed teasing some of our international biochemical colleagues. At meetings he would have the vial in his pocket. He would talk about adrenochrome and after the colleague had finished telling him that it could not be made stable, could not be crystallized and could not be made in the body because of its remarkable instability he would pull out the little vial of crystalline adrenochrome and show it to the discomfited authority. Before that the preparations were very unstable and the first one made for us had to stored at minus 40 Degrees Centigrade. But one day when I was in Vancouver at the faculty club University of British Columbia I had lunch with an English organic chemist and I discussed with him the problems with unstable adrenochrome. He replied that usually unstable organic chemicals were not pure. That was the answer. I suddenly realized that the silver used in converting adrenalin to adrenochrome had not been removed. I immediately wrote a note to my chemist not Dr Heacock who had not yet joined us ; to take the adrenochrome and to pour a solution of the adrenochrome through a carbon column to strip all the silver out. When I came home I went to the lab to see what had happened and discovered that my chemist had not done it. I was very angry. That afternoon he came to me and showed me the first ever pure crystals. Taking out all the silver had made it stable. Later we sent samples to Prof Mark Alchule of Harvard and McLeans Hospital in Boston and to Dr S Udenfriend of NIMH in Washington DC. Later when NIMH was so anxious to prove us wrong Dr Seymour Kety reported at one of the meetings I attended that Dr Julius Axelrod proved that adrenochrome could not be made in the body. He described with glee how his friend and colleague who later got the Nobel Prize for some of his other work had asked Udenfriend for a small 4 Hoffer A & Osmond H: 1967. The Hallucinogens. Academic Press, New York. An extension of the therapeutic action. Not surprisingly, the major problem with the currently used anticancer drugs is their toxicity toward noncancerous cells. To reduce this undesirable toxicity of antineoplastics, various approaches have been taken to improve their therapeutic indices. One approach has been to exploit the stereoselective toxicity of some chiral antitumor agents. Cyclophosphamide, for example, contains a chiral center at the phosphorus atom and is used clinically as its racemic form. Cox et al. Cox et al., 1976a, b ; reported that the ; -enantiomer of cyclophosphamide had twice the therapeutic index LD50 ID90 ; of the ; -enantiomer against the ADJ PC6 cell turnover in mice. In clinical applications, however, there was no significant therapeutic advantage gained by using the single enantiomer. In the past, barbiturates were used extensively as hypnotics. These compounds are rarely used today because of the numerous adverse reactions that have been associated with their use. One of the untoward effects of barbiturates is their excitatory aftereffects. The excitation phenomena range from mild tremors to conclusive seizures. 5- 1, 3-dimethylbutyl ; -5-ethyl barbituric acid DMBB ; has been used extensively in the investigation of the mechanism of the excitatory effects associated with barbiturate administration. The S- ; -DMBB isomer induced extensive seizures, whereas the R- ; -isomer induced preanesthetic excitation without seizures Downes et al., 1970; Downes and Williams, 1969 ; . The LD50 of the S- ; -DMBB in mice was 3 mg kg i.v., whereas that of the R- ; -isomer was 72 mg kg i.v., indicating stereoselective toxicity in that species. The hypnotic drug thalidomide was taken off the market in Europe after it was tragically found to cause a rare birth defect known as phocomelia. The tragedy led to the passage of the Harris-Kefauver Amendment to the Federal Pure Food and Drug Act in the United States in 1962 to ensure that approved drugs have proof of safety and efficacy Blaschke et al., 1985 ; . Thalidomide contains a chiral center, and both enantiomers are equally sedating; thus, during its use it was supplied as the racemate. In studies with mice and rats, Blaschke and his coworkers Blaschke et al., 1979; Blaschke, 1980 ; found that the S-enantiomer of thalidomide was teratogenic, whereas the R-isomer was not teratogenic. After intraperitoneal administration of the S-enantiomer 200 mg kg day ; to pregnant animals, the percentage of fetuses born deformed was approximately 30% in mice and 50% in rats. However, no deformed fetuses were found when the R-isomer was given intraperitoneally at the same dose to a similar population of animals. By contrast, both enantiomers of thalidomide appeared to be equally teratogenic when administered to rabbits, and the racemate appeared to be even more teratogenic Fabro et al., 1967; Simonyi, 1984 ; . The percentage of deformed fetuses born from rabbits which were given these treatments was approximately 40% for the racemate, but only 16 to 17% for either S- or R-enantiomer and mesylate. [2] Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiat 1922; 8: 184-196. [3] Kasanin J. The blood sugar curve in mental disease. Arch Neurol psychiat 1926; 16: 414-419 [4] Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. J Psychiatry 1945; 102: 108-110 [5] Charaten FBE, Bartlett NG. The effect of chlorpromazine on glucose tolerance. J Mental Sci 1955; 191: 351-353. [6] Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Archives Gen Psychiatry 2004; 60: 553-564. [7] Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. J Psychiatry 1999; 156: 1686-1696. [8] Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 20, 2006; 5: [9] Roth BL, Sheffler D, Potkin SG: Atypical antipsychotic drug actions: unitary or multiple mechanisms for "atypicality"? Clinical Neuroscience Research 2003; 3: 10717. [10] Kapur S, Seeman P: Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25: 161-166. [11] Clark NG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601. [12] Harris EC, Barraclough BM. Excess mortality of mental disorders. Brit J Psychiatry 1998; 173: 11-53. [13] Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiat 1991; 36: 239-245. [14] Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37 1 ; : 68-73. [15] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 S1 ; : S5-S20. [16] Cohen D. Atypical antipsychotics and new onset of diabetes mellitus. Pharmacopsychiatry 2004 ; 37 1 ; : 1-11. [17] Libiger J. Diabetes in patients treated with antipsychotics [in Czech]. Vnitrni lekarstvi 2004; 51 S2 ; : S88-S93.

DOLOGESIC. 19 DOLOPHINE. 22 dolorex . 53 DOLOREX FORTE. 23 dolotic . 42 DONATUSSIN . 74 DORYX . 14 DOSTINEX. 46 DOVONEX. 37 doxazosin. 35 doxepin. 28, 40 DOXIL . 16 doxorubicin . 16 doxycycline. 14, 43 doxycycline hyclate . 43 drexophed sr. 70 drihist sr . 70 DRITHO-SCALP. 37 drixomed . 70 DROXIA . 16 DRUGS AFFECTING THE EAR . 41 DRUGS AFFECTING THE NOSE . 42 drysec . 70 DRYSOL. 39 d-tann . 70 DTIC-DOME . 16 DUAC . 36 DUET. 63 duomax. 74 duonate. 70 DUOTAN. 70 duotan pd . 70 DURABAC . 53 DURABAC FORTE . 53 DURACLON . 31 duradryl. 70 durafed . 70 DURAGESIC 12mcg patch . 22 DURAGESIC 25mg, 50mg, 75mg, . 22 DURAHIST D . 70 DURAHIST, PE. 70 DURAMORPH . 22 DURAPHEN II . 75 durasal ii . 75 DURATUSS, GP . 75 DURAXIN . 53 DURICEF . 8 DYAZIDE. 34 dyflex-g. 78 dy-g . 78 dygase . 48 dylix. 78 and catapres.

13. Debruyne FMJ. Alpha blockers: are all created equal? Urology 2000; 56 s5A ; : 20 2. 14. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. JAMA 1992; 267: 1244 Sapolsky RM. Neuroendocrinology of the stress response. In Becker JB, Breedlove SM, Crews D, eds. Behavioral Endocrinology. Cambridge, MA: MIT Press, 1992: 287324. 16. Mills PJ, Ziegler MG, Patterson T, Dimsdale JE, Hauger R, Irwin M, Grant I. Plasma catecholamine and lymphocyte beta-sub-2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress. Psychosom Med 1997; 59: 251 Mazur A, Michalek J. Marriage, divorce, and male testosterone. Social Forces 1998; 77: 31530. Dell'Erba G, Pancheri P, Intreccialagli B. Hormonal assessment and workload correlates in air traffic controllers at the end of night shift: the stress perspective. New Trends in Experimental & Clinical Psychiatry 1988; 4: 197212. Aakvaag A, Bentdal O, Quigstad K, Walstad P, Rohnnongen H, Fonnum F. Testosterone and testosterone-binding globulin TeBG ; in young men during prolonged stress. Int J Androl 1978; 1: 2231. Kreuz LE, Rose RM, Jennings JR. Suppression of plasma testosterone levels and psychologicalal stress. Arch Gen Psychiatry 1972; 26: 479 Thompson WM, Dabbs JM, Frady RL. Changes in salivary testosterone levels during a 90-day shock incarceration program. Criminal Justice and Behavior 1990; 17: 246 Nilsson PM, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med 1995; 237: 479 Spielberger CD, Johnson EH, Russell SF, Crane RJ, Jacobs GA, Worden TJ. The experience and expression of anger: Construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, eds. Anger and Hostility in Cardiovascular and Behavioral Disorders. New York: McGraw-Hill, 1985: 530. 24. Hardy JD, Smith TW. Cynical hostility and vulnerability to disease: social support, life stress, and physiological response to conflict. Health Psychol 1988; 7: 44759. Christensen, AJ, Smith TW. Cynical hostility and cardiovascular reactivity during self-disclosure. Psychosom Med 1993; 55: 193202. Suarez EC, Williams RB. Situational determinants of cardiovascular and emotional reactivity in high and low hostile men. Psychosom Med 1989; 51: 404 Suarez EC, Kuhn CM, Schanberg SM, Williams R, Zimmerman EA. Neuroendocrine, cardiovascular, and emotional responses of hostile men: the role of interpersonal challenge. Psychosom Med 1998; 60: 78 Stone AA, Mezzacappa ES, Donatone BA, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol 1999; 18: 482 McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms MTOPS ; Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol 1978; 46: 932 Russo J, Vitaliano PP. Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease. Exp Aging Res 1995; 21: 27394. Kessler RC, Wethington E. The reliability of life events reports in a community survey. Psychol Med 1991; 21: 72338. Leserman J, Murphy C, Evans DL. Stress Rating Manual for the Coping in Health and Illness Project CHIP ; . Chapel Hill: University of North Carolina, 2000. 34. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor of early disease progression in HIV infection. J Psychiatry 1997; 154: 630 Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol 1992; 63: 4529. And 1, 066 without this diagnosis ; . The results indicated that the risk of these hypotensive-related events increased after the initiation of nonprostate-specific -blockers for BPH treatment. For example, among men without hypertension, there was a 1.1% excess incidence of fractures, with fractures of the hip or pelvis accounting for 54% of all fractures. In contrast, several studies have confirmed that tamsulosin has negligible effects on blood pressure and does not cause clinically meaningful orthostatic changes.10, 18, 19 These negligible effects indicate that the medical services and costs associated with blood pressure monitoring and treatment of blood pressure-related side effects can be minimized. These lower costs may work to offset the higher drug acquisition costs for tamsulosin compared with the older 1-antagonists, all now available as generic drugs. ss Pharmacoeconomic Methods Model Structure The basic structural elements of the decision model used to evaluate the cost-effectiveness of tamsulosin are illustrated in Figure 1. Treatment is initiated with tamsulosin, terazosin, or doxazosin. Terazosin and doxazosin were selected as 1-antagonists comparators with tamsulosin because they generally are prescribed for once-daily dosing, as is tamsulosin. Prazosin was not included because it generally is prescribed for twice-daily dosing and, in current practice, is rarely used to treat BPH.17 Patients at initiation are defined as newly diagnosed treatment nave ; or patients who have failed "watchful waiting" who have American Urological Association AUA ; symptom scores in the moderate range at baseline. After initiation of therapy, over the initial 6 months, the therapy is either successful or unsuccessful, where treatment success is defined as a 25% improvement in AUA symptom score from baseline. If the initial therapy is successful at 6 months, the patient continues on the therapy for another 6 months. If the initial therapy is successful at the end of 12 months, the patient continues on the therapy for another 6 months, and so on, for 3 years. However, if the initial therapy fails, subsequent therapy is modified. A 25% improvement from baseline AUA symptom score is a commonly specified end point in clinical trials of drug therapies for BPH. Other common end points include the absolute change in AUA symptom score, change in mean peak urinary flow rate, and postvoid urine retention. The model focuses on the percentage achieving a 25% or better improvement in AUA symptom score for several reasons. First, this outcome metric corresponds to a clinically relevant concept of "treatment success" for patients with moderate BPH symptoms that fits naturally within a clinical decision-model framework. In other words, the model assumes that modifications in treatment are triggered by lack of treatment success rather than specific values of clinical parameters. Second, the various outcome measures tend to be highly correlated. Though we have not. Cardura XL doxazosin; Pfizer ; tablets 4mg and 8mg are currently out of stock.The company says intermittent stock problems may continue in the short term and mesylate. Hwang JJ, Uchio EM, Pavlovich CP, Pautler S, Libutti SK, Linehan WM, Walther MM. Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach. J Urol 2003 March: 169 3 ; : 895-8. Hwang JJ, Dharmawardana PG, Uchio EM, Wynberg J, Phillips JL. Prostate cancer in Klinefelter syndrome during hormonal replacement therapy. Urology 2003 Nov: 62 5 ; : 941. Hwang JJ, Uchio EM, Linehan WM, Walther MM. Follow up Strategies and Management of Recurrence in Urologic Oncology Renal Cancer Familial. Hereditary Kidney Cancer. Urol Clin North 2003 Nov: 30 4 ; : 831-42. Hwang J, Shoaf G, Uchio EM, Watson J, Pacak K, Linehan WM, Walther MM. Laparoscopic management of extra-adrenal pheochromocytoma. J Urol 2004 Jan: 171 1 ; : 72-6. Kim N. Cao W. Song IS. Kim CY. Harnett KM. Cheng L. Walsh MP. Biancani P. Distinct kinases are involved in contraction of cat esophageal and lower esophageal sphincter smooth muscles. J Physiol - Cell Physiol 2004, 287 2 ; : C384-94. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE Jr, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. NEJM 349 25 ; 2385-2396, 2003. Peschel RE. Colberg JW. The modern era: Surgery, brachytherapy, and external beam radiation therapy for early prostate cancer. The Lancet Onc 2003, 4: 233-241. Renzulli JF, Borromeo JR, Barkhordarian S, Sumpio BE. Abdominal aortic aneurysm in association with a congenital pelvic horseshoe kidney: sentinel report and technical consideration. Vascular Med 2003, 8 3 ; : 1979. Shnorhavorian M, Foster HE Jr. Surgical Management of Complex Neurogenic Urinary Incontinence in Female patients: The 10-Year Yale Experience. NE AUA Annual Mtg. 144, 2004 Sept. Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 62: 162-166, 2003. Takahashi W, Yono M, Wada Y, Ikeda K, Weiss RM, Latifpour J. Regulatory effect of castration on endothelins, their receptors and endothelin converting enzyme in the rat seminal vesicle. BJU Int 92: 803-809, 2003. Uchio EM, Linehan WM, Figg WD, Walther MM. A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. J Urol 2003 Jan: 169 1 ; : 357-360. Xiao ZL. Biancani P. Carey MC. Behar J. Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis. Hepatology 2003, 37 6 ; : 1442-50. Xiao ZL. Biancani P. Behar J. Role of PGE2 on gallbladder muscle cytoprotection of guinea pigs. J Physiol - GI & Liver Physiol 2004, 286 1 ; : G82-8.

Certain clinical features help to distinguish allergy from other reactions: • only a small number of patients react in this way • minute doses may trigger a response • the signs and symptoms are similar to those of allergic responses triggered by other substances foods, animals, insect stings ; • they develop soon after the drug is started and resolve soon after it is withdrawn • they are quite different from the usual pharmacological actions of the drug • specific tests may define the allergic response principles of testing testing is primarily restricted to the detection of drugspecific ige antibodies.
Washington Hospital Center HIV Services Infectious Diseases 110 Irving St., NW Washington, DC 20010 202 ; 877-0333 new patients ; Taylor Medical Center Whitman-Walker Clinic 1701 14th St., NW Washington, DC 20009 202 ; 797-3500 new patients ; 202 ; 332-EXAM. Why not? "The reality is no one promotes a diuretic, " said Mr Brode. "So you've got one study that says yes, you should [use a diuretic], then starting the day after, you've got a $10bn [6.2bn; 9.5bn] industry . and 55 promotional events . for an ACE inhibitor coming back in and saying `Here's why my ACE inhibitor is safe and here's why you should be using this.' I mean, it's promotion. Can ALLHAT stand up to that?" Mr Brode, despite his rosy predictions regarding sales, didn't challenge the ALLHAT results, saying instead: "Great data. Very solid. Didn't surprise anybody . but nobody's promoting diuretics." But if Dr Curt Furberg, chair of the ALLHAT steering committee, has his way, that won't be the case. He and other ALLHAT staff are staying on to disseminate the data. He says that expensive calcium channel blockers and ACE inhibitors may be costing an excess of $8bn to $10bn--without providing any benefit to patients, and in some instances adding more risk. Why was so much money wasted for so many years on drugs that weren't as good? Dr Furberg says, "We just didn't know." But why didn't they know? The practice of testing new medicines against placebo, rather than against the best treatment available, has contributed to a general lack of knowledge. But spin doctoring clearly triumphed when a head-to-head comparison provided at least one answer. In March 2000 the ALLHAT researchers halted the blocker arm of the trial when it was found that doxazosin Cardura ; was inferior to a diuretic. Patients on Cardura, dubbed a "miracle drug" by a Pfizer executive, experienced a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on a diuretic, results published in the 19 April 2000 issue of JAMA show. Pfizer, aware of the results before publication, launched a sophisticated damage control campaign in early 2000. Sales of Cardura, estimated at $800m 500m; 760m ; worldwide in 2000, continued virtually unaffected by the study for the rest of the year. Just how Pfizer managed this feat is revealed by internal drug company documents filed in January 2001 as part of a "citizen's petition" against Pfizer. The plan included using an outside research agency to study doctors' awareness of the ALLHAT results. When the agency found that "knowledge of the trial's preliminary results is minimal for all specialties, " they took steps to avoid sullying that lack of awareness. Pfizer decided not to issue a public statement about the ALLHAT results because doing so "would likely draw more media attention to the situation." They instructed their drug reps to provide information about ALLHAT "only when asked." Finally, two enterprising Pfizer employees were praised as "quite brilliant" for "sending their key doctors to sightsee" during a presentation at the annual American College of Cardiology conference in California in 2000. The doctors, from Italy, were brought to California by Pfizer. The tour, according to the Pfizer email praising the reps, kept the doctors from attending Dr Furberg's presentation of the ALLHAT results. But Pfizer was not alone in blunting the response to ALLHAT results. The American College of Cardiology ACC ; issued an alert in March 2000 urging doctors to "discontinue use" of Cardura. However, another Pfizer memo dated 28 March 2000 and stamped "confidential" says that Pfizer was "successful in getting the ACC to agree to a clarification" of the ACC press release. The "clarification" that the ACC agreed upon replaced its initial press release on the ACC website within just hours of the original posting and changed the recommendation that Cardura be discontinued to a much milder recommendation that doctors "reassess" its use. It may have added to Pfizer's standing with the ACC that Pfizer has contributed more than $500 000 312 000; 474 000 ; annually to the college in recent years. Do not take tadalafil if you are taking the following medications: • alpha blockers, such as alfuzosin uroxatral® , doxazosin cardura® , prazosin minipress® , or terazosin hytrin® , used to treat high blood pressure or an enlarged prostate. Reduce drug related crime and disorder strengthen community partnership disrupt drug markets.

Doxazosin what is

Aden 86, tumor stage, ulcerative colitis help, quetiapine serum level and whitehead law firm. Tacrolimus mechanism, women's hospital at renaissance edinburg, hand foot and mouth disease medical term and affinity guild or pletal heart failure.

Doxazosin pliva

Doxazosin mesylate 1 mg, doxazosin side effects medication, doxazosin mesyl side effects, doxazosin mesylate 4 mg tab and side effects of doxazosin mesylate. Doxaosin dangers, doxazosin what is, doxazosin pliva and doxazosin mesylate 1mg side effects or doxazosin side effects drugs.